Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

December 10, 2016
Hope S. Rugo, MD

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses what sets abemaciclib apart from other CDK 4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.